-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $270

Benzinga·06/26/2026 14:42:32
Listen to the news
Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $266 to $270.